CSCI/RCPSC Henry Friesen Lecture: Cell therapy for Duchenne Muscular Dystrophy

Tremblay, Jaques P.
December 2006
Clinical & Investigative Medicine;Dec2006, Vol. 29 Issue 6, p378
Academic Journal
The article focuses on the cell therapy for Duchenne muscular dystrophy (DMD). DMD, which is a fatal hereditary disease, is caused by an X-linked genetic defect resulting to absence of dystrophin. Among the approaches for treating DMD is gene therapy, which aims to direct dystrophin gene in the patient's muscle therapy. Key information regarding the clinical trial of cell therapy are further discussed.


Related Articles

  • Recent advances in Duchenne muscular dystrophy. Perkins, Kelly J.; Davies, Kay E. // Degenerative Neurological & Neuromuscular Disease;2012 Part 2, Vol. 2, p141 

    Duchenne muscular dystrophy (DMD), an allelic X-linked progressive muscle-wasting disease, is one of the most common single-gene disorders in the developed world. Despite knowledge of the underlying genetic causation and resultant pathophysiology from lack of dystrophin protein at the muscle...

  • Gene Therapy in Duchenne Muscular Dystrophy. Pichavant, Christophe; Tremblay, Jacques P. // Gene Therapy Review;Jul2009, Vol. 1 Issue 1, p32 

    The article describes various methods of introduction of the dystrophin cDNA or its truncated versions in muscles as a cell transplantation technique for the treatment Duchenne muscular dystrophy. The authors assert that using adeno-associated virus (AAV) vector is the best method for the direct...

  • Exploring the Frontiers of Therapeutic Exon Skipping for Duchenne Muscular Dystrophy by Double Targeting within One or Multiple Exons. Aartsma-Rus, Annemieke; Kaman, Wendy E.; Weij, Rudie; den Dunnen, Johan T.; van Ommen, Gert-Jan. B.; van Deutekom, Judith C. T. // Molecular Therapy;Sep2006, Vol. 14 Issue 3, p401 

    Through antisense-induced single-, double-, and multiexon skipping, we have previously demonstrated restoration of dystrophin expression in Duchenne muscular dystrophy (DMD) patient-derived muscle cells in vitro. In this study we further explored the frontiers of this strategy by using specific...

  • Tremblay lab.  // Gene Therapy Review;Jul2009, Vol. 1 Issue 1, p50 

    The article provides information on the research for the treatment of Duchenne muscular dystrophy (DMD) conducted in Tremblay laboratory. It notes that the focus of the research is on genetically modified Muscle Precursor Cells (MPCs) transplantation into muscles for the restoration of...

  • Gene Therapy for Muscular Dystrophies: Current Status and Future Prospects. Takeda, S.; Miyagoe-Suzuki, Y. // BioDrugs;2001, Vol. 15 Issue 10, p635 

    Since the identification in 1987 of the gene for Duchenne muscular dystrophy (DMD), research on the molecular pathogenesis of muscular dystrophy has progressed extensively. In particular, discovery of the DMD gene product, dystrophin, led to the identification of dystrophin-associated proteins...

  • In vivo correction of muscular dystrophy. Jamison, Judy // Nature Biotechnology;Jun2000, Vol. 18 Issue 6, p586 

    Discusses that gene therapy for Duchenne muscular dystrophy (DMD) has failed to produce long-term stable expression of the dystrophin gene product. Reasons for the failure of gene therapy for DMD; Use of chimeric oligonucleotides to repair sickle cell mutations.

  • A novel miniDys_eGFP fusion gene for developing cell_based therapies of Duchenne muscular dystrophy  // Molecular Therapy;May2004 Supplement 1, Vol. 9, p93 

    An abstract of the article "A Novel MiniDys-eGFP Fusion Gene for Developing Cell-Based Therapies of Duchenne Muscular Dystrophy," by Sheng Li, En Kimura, Leonard Meuse, Xin Ye, Brent Fall, Steven D. Hauschka, John Faulkner and Jeffrey S. Chamberlain is presented.

  • Modular flexibility of dystrophin: Implications for gene therapy of Duchenne muscular dystrophy. Harper, Scott Q.; Hauser, Michael A.; DelloRusso, Christiana; Duan, Dongsheng; Crawford, Robert W.; Phelps, Stephanie F.; Harper, Hollie A.; Robinson, Ann S.; Engelhardt, John F.; Brooks, Susan V.; Chamberlain, Jeffrey S. // Nature Medicine;Mar2002, Vol. 8 Issue 3, p253 

    Attempts to develop gene therapy for Duchenne muscular dystrophy (DMD) have been complicated by the enormous size of the dystrophin gene. We have performed a detailed functional analysis of dystrophin structural domains and show that multiple regions of the protein can be deleted in various...

  • DYS-HAC-iPS Cells: The Combination of Gene and Cell Therapy to Treat Duchenne Muscular Dystrophy. In-Hyun Park // Molecular Therapy;Feb2010, Vol. 18 Issue 2, p238 

    The article presents the author's views on gene and cell therapy to treat Duchenne muscular dystrophy (DMD). He reports that DMD is the most prevalent genetic disorder among newborn infants. He discusses the use of human artificial chromosomes to express dystrophin to induce pluripotent stem...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics